According to a story from BioPortfolio, the biopharmaceutical company AVEO Pharmaceuticals and the lung cancer diagnostic company Biodesix recently released the results from the Phase Ib clinical trial testing a…
.jpg)
The oral inhibitor drug gilteritinib (XOSPATA®) was recently approved by the FDA based on interim results of the clinical trial ADMIRAL, according to an article in EurekAlert for Science News. A…
Acute Myelogenous Leukemia Acute myelogenous leukemia (AML) is a rare blood cancer whose prevalence increases with age. There are still extremely limited treatment options for AML and the five-year survival…
The very first patient in Medigene AG's clinical trial examining MDG1011 has officially received the treatment. This is the company's first human clinical trial for this TCR therapy. The trial…
The Food and Drug Administration (FDA) recently announced its approval of Venetoclax (Venclexta) in combination with either decitabine or azacitidine (hypomethylating agents) or cytarabine (an antimetabolite) to treat adults 75 years…
A report published in 2018 in The Hemotologist mentions the fact that most of the therapies introduced over the years for acute myeloid leukemia (AML) simply meant optimizing the use of…
According to a story from Science Daily, an experimental therapy for cancer could shut down tumor cells using an innovative mechanism that disrupts their circadian rhythm functions. A concept study…
The State of Cancer in the United States A recent report posted by the American Cancer Society has indicated that cancer rates in the United States have been continuously falling over…
The government shutdown hasn't had any startling affects on rare disease research yet, but drug developers have voiced their concern that it could soon begin to hinder the research process.…
Myelodysplastic syndromes (MDS) is the name used to describe a group of stem cell disorders in which the body can't produce an adequate amount of platelets and blood cells. Currently,…
Dr. Louis J. DeGennaro, who is the CEO and President of the Leukemia & Lymphoma Society, has recently contributed a blog post on the organization's website. In this post, Dr.…
According to a story from the National Post, 34-year-old mother Andrea Cardin, a photographer, was excited to welcome her newborn son James into the world on November 21st of this…
At four years old, Norah Gratz-Lazarus of California is a sweet, bubbly girl, full of spirit. She's a big sister, and loves jokes, ice cream, and chocolate chip cookies. However, Norah…
According to a publication from MarketScreener, pharmaceutical titan Pfizer Inc. has gained FDA approval for Daurismo, a once-a-day oral medication designed to be paired with low-dose cytarabine (a type of…
According to a story from investors.amgen.com, the drug developer Amgen recently announced its intent to present all new clinical trial data which will feature its latest work in testing a…
An innovative new treatment means practically nothing if we can't determine the type of patient it's going to be effective for. For an illness like acute myeloid leukemia (AML), which is…
The Scottish Medicines Consortium, a committee that advises NHS Scotland on what medicines they should provide, has accepted four new drugs for use. These are gemtuzumab ozogamicin for acute myeloid…
Over the weekend, the New York Times ran an opinion piece that caught our attention. "He Got Schizophrenia. He Got Cancer. And Then He Got Cured." Click here to read…
According to a story from ncb29.com, Tina Moore initially attributed her easy bruising to an infection. However, when she decided to get some blood work done, her doctors told her…
McMaster University researchers investigating the factors underlying patient relapse in acute myeloid leukaemia believe that they may have found a type of cell that plays an important role. The researchers…
According to a story from Medpage Today, three recent research studies have managed to reveal new biomarkers for myelodysplastic syndromes. Biomarkers are a crucial factor for understanding a medical condition…
The company Imago Biosciences, which focuses on developing anti-cancer therapies, is carrying out a Phase 1/2a clinical study of an investigational drug called IMG-7289 as a potential treatment for…
The United States Adopted Name Council, which selects simple, new, and informative generic drug names, has approved ‘Onvansertib’ as the generic name for PCM-075. PCM-075 is an investigational drug that…
Two companies, Tolero Pharmaceuticals Inc. and AbbieVie, have agreed to collaborate to clinically research a potential combination therapy for relapsed or refractory acute myeloid leukaemia. The potential therapy is comprised…
A Biologics License Application for ElzonrisTM (also known as tagraxofusp and SL-401) for the treatment of blastic plasmacytoid dendritic cell neoplasm has been accepted for filing by the United States FDA.…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
